SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT RESPONDING TO ANTIVIRAL COMBINATION THERAPY
SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT RESPONDING TO
ANTIVIRAL COMBINATION THERAPY
Reported by Jules Levin
43rd EASL
April 23-27, 2008-05-01Milan, Italy
Peter Ferenci, Thomas M. Scherzer,
Harald Hofer, Katharina Staufer, Petra Munda
Internal Medicine 3
Medical University of Vienna
AUSTRIA
This study was supported by an unrestricted research grant by ROCHE Austria,
Silibinin was provided by ROTTAPHARM-MADAUS free of charge
AUTHOR SUMMARY
iv. silibinin has potent antiviral activity against HCV
This effect is dose dependent, and independent of peginterferon/ribavirin
iv. silibinin was well tolerated
oral administration of silymarin was ineffective
AUTHOR CONCLUSIONS
iv. silibinin may be useful for treatment of nonresponders to
peginterferon/ribavirin
the optimal dose and duration of silibinin therapy remains to be studied
Studies of the pharmacokinetics of silibinin are mandatory
The mechanism of action is unknown
Silymarin
Silymarin is a potentially useful drug for treatment of liver diseases
-- Clinical studies not conclusive
--mode of action
antioxidant/free radical scavenger
antifibrotic
Hepatoprotective (Amanita phalloides)
Study 1
Decrease of oxidative stress by high dose silibinin Ð improved efficacy of
interferon?
Pedigreed nonresponders
Full dose peginterferon/RBV for at least 12 weeks
-- < 2log drop week 12
-- HCV-RNA pos.at week 24
Click on link for slides: http://www.natap.org/2008/EASL/EASL_57.htm
Treatment of Chronic Hepatitis C with Telaprevir (TVR) in Combination with
Peginterferon Alfa-2a with or without Ribavirin: Interim Results of the PROVE2
Study - (05/02/08)
a.. SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT
RESPONDING TO ANTIVIRAL COMBINATION THERAPY - (05/02/08)
b.. Results of a Safety, Tolerability and Pharmacokinetic Phase I Study of
VCH-916, a Novel Polymerase Inhibitor for HCV, Following Single Ascending Doses
in Healthy Volunteers - (05/02/08)
Preclinical Pharmacokinetic and ADME Characterization of VCH-916, a Novel
Non-Nuclesoside HCV NS5B Polymerase Inhibitor - (05/02/08)
Interim Results from HCV SPRINT-1: RVR/EVR from Phase 2 Study of Boceprevir Plus
Peginterferon alfa-2b/Ribavirin in Treatment-Naive Subjects with Genotype-1 CHC
- (04/30/08)
a.. RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF NITAZOXANIDE IN THE
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 - (05/16/08)
b.. EVALUATION OF A 4 WEEK LEAD-IN PHASE WITH NITAZOXANIDE PRIOR TO
NITAZOXANIDE+PEGINTERFERON IN TREATING CHRONIC HEPATITIS C - (05/16/08)
POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR, R7128, IN
COMBINATION WITH PEG-IFN a-2a AND RIBAVIRIN - (05/06/08)
High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon
alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon
alfa-2a and ribavirin- (05/06/08)
a.. HCV Protease Inhibitor Telaprevir, PROVE1 Study: final results of a phase
2 study with peginterferon plus ribaviron in treatment-naive patients with
hepatitis C - (04/25/08)
b.. A Study of Telaprevir (TVR) with Peginterferon Alfa-2a (P) and Ribavirin
(R) in Subjects with Well-Documented Prior PR Null Response, Non-Response or
Relapse: Preliminary Results - (04/25/08)